Literature DB >> 29174391

Prediction of Long-Term Survival After Lung Cancer Surgery for Elderly Patients in The Society of Thoracic Surgeons General Thoracic Surgery Database.

Mark W Onaitis1, Anthony P Furnary2, Andrzej S Kosinski3, Sunghee Kim3, Daniel Boffa4, Betty C Tong3, Patricia Cowper3, Jeffrey P Jacobs5, Cameron D Wright6, Joe B Putnam7, Felix G Fernandez8.   

Abstract

BACKGROUND: Prior risk models using the STS General Thoracic Surgery database (STS-GTSD) have been limited to 30-day outcomes. We have now linked STS data to Medicare data and sought to create a risk prediction model for long-term mortality after lung cancer resection in patients older than 65 years.
METHODS: The STS-GTSD was linked to Medicare data for lung cancer resections from 2002 to 2013 as previously reported. Successful linkage was performed in 29,899 lung cancer resection patients. Cox proportional hazards modeling was used to create a long-term survival model. Variable selection was performed using statistically significant univariate factors and known clinical predictors of outcome. Calibration was assessed by dividing the cohort into deciles of predicted survival and discrimination assessed with a C-statistic corrected for optimism via 1,000 bootstrap replications.
RESULTS: Median age was 73 years (interquartile range, 68 to 78 years), and 48% of the patients were male. Of the 29,094 patients with nonmissing pathologic stage, 69% were stage I, 18% stage II, 11% stage III, and 2% stage IV. Procedure performed was lobectomy in 69%, bilobectomy in 3%, pneumonectomy in 3%, segmentectomy in 7%, sleeve lobectomy in 1%, and wedge resection in 17%. Thoracoscopic approach was performed in 47% of resections. The final Cox model reveals that stage and age are the strongest predictors of long-term survival. Even after controlling for stage, wedge resection, segmentectomy, bilobectomy, and pneumonectomy are all associated with increased hazard of death in comparison with lobectomy. Thoracoscopic approach is associated with improved long-term survival in comparison with thoracotomy. Other modifiable predictive factors include smoking and low body mass index. Calibration of the model demonstrates excellent performance across all survival deciles and a C-statistic of 0.694.
CONCLUSIONS: The STS-GTSD-Medicare long-term risk model includes several novel factors associated with mortality. Although medical factors predict long-term survival, age and stage are the strong predictors. Despite this, procedure choice and thoracoscopic/open approach are potentially modifiable predictors of long-term survival after lung cancer resection.
Copyright © 2018 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29174391     DOI: 10.1016/j.athoracsur.2017.06.071

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  11 in total

1.  Oncologic validity of minimally invasive lobectomy for early stage lung cancer.

Authors:  Todd L Demmy; Sai Yendamuri
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

2.  Surgical Outcomes for Early Stage Non-small Cell Lung Cancer at Facilities With Stereotactic Body Radiation Therapy Programs.

Authors:  Yusef A Syed; William Stokes; Manali Rupji; Yuan Liu; Onkar Khullar; Nikhil Sebastian; Kristin Higgins; Jeffrey D Bradley; Walter J Curran; Suresh Ramalingam; James Taylor; Manu Sancheti; Felix Fernandez; Drew Moghanaki
Journal:  Chest       Date:  2021-11-14       Impact factor: 9.410

3.  A nomogram for predicting the risk of lymph node metastasis in T1-2 non-small-cell lung cancer based on PET/CT and clinical characteristics.

Authors:  Xiayi Lv; Zhigang Wu; Jinlin Cao; Yeji Hu; Kai Liu; Xiaona Dai; Xiaoshuai Yuan; Yiqing Wang; Kui Zhao; Wang Lv; Jian Hu
Journal:  Transl Lung Cancer Res       Date:  2021-01

4.  Association of performance in a stair-climbing test with complications and survival after lung cancer resection in the video-assisted thoracoscopic surgery era: population-based outcomes.

Authors:  Olli Helminen; Johanna Valo; Heidi Andersen; Johan Söderström; Eero Sihvo
Journal:  ERJ Open Res       Date:  2021-08-16

5.  Twenty-Year Survival of Patients Operated on for Non-Small-Cell Lung Cancer: The Impact of Tumor Stage and Patient-Related Parameters.

Authors:  Olivier Schussler; Antonio Bobbio; Hervé Dermine; Audrey Lupo; Diane Damotte; Yves Lecarpentier; Marco Alifano
Journal:  Cancers (Basel)       Date:  2022-02-10       Impact factor: 6.639

6.  Pneumonectomy for primary lung cancer: contemporary outcomes, risk factors and model validation.

Authors:  Annemarie Brunswicker; Marcus Taylor; Stuart W Grant; Udo Abah; Matthew Smith; Michael Shackcloth; Felice Granato; Rajesh Shah; Kandadai Rammohan
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-06-01

7.  Postoperative atrial fibrillation prophylaxis using a novel amiodarone order set.

Authors:  Joseph D Phillips; Eleah D Porter; Brendin R Beaulieu-Jones; Kayla A Fay; Rian M Hasson; Timothy M Millington; David J Finley
Journal:  J Thorac Dis       Date:  2020-06       Impact factor: 3.005

8.  Clinical significance of C-Reactive Protein to Lymphocyte Count Ratio as a prognostic factor for Survival in Non-small Cell Lung Cancer Patients undergoing Curative Surgical Resection.

Authors:  Jae-Joon Hwang; Joon Young Hur; Wankyu Eo; Soomin An; Dae Hyun Kim; Sookyung Lee
Journal:  J Cancer       Date:  2021-05-27       Impact factor: 4.207

Review 9.  Segmentectomy and Wedge Resection for Elderly Patients with Stage I Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Authors:  Peiyu Wang; Shaodong Wang; Zheng Liu; Xizhao Sui; Xun Wang; Xiao Li; Mantang Qiu; Fan Yang
Journal:  J Clin Med       Date:  2022-01-06       Impact factor: 4.241

10.  Preliminary Results of the Outpatient Endovascular and Interventional Society National Registry.

Authors:  Samuel S Ahn; Robert W Tahara; Lauren E Jones; Jeffrey G Carr; John Blebea
Journal:  J Endovasc Ther       Date:  2020-08-19       Impact factor: 3.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.